IPHA News and Press, Innate Pharma S.A. From 12/11/23

SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in patients with R/R A...

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET) In...

The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral presentation at the American Society of Hematology (ASH) Annual Meeting Virtual K...

2023-11-14 17:56:04 ET Innate Pharma S.A. (IPHA) Q3 2023 Earnings Conference Call November 14, 2023, 08:00 AM ET Company Participants Henry Wheeler - VP, IR and Communication Mondher Mahjoubi - CEO Sonia Quaratino - Chief Medical Officer Yannis Morel - EVP, B...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Innate Pharma S.A. (IPHA) is expected to report for Q3 2023

2023-11-14 02:33:48 ET More on Innate Pharma Innate Pharma slips on FDA clinical hold Seeking Alpha’s Quant Rating on Innate Pharma Historical earnings data for Innate Pharma Financial information for Innate Pharma For further details see: ...

Positive final results of lacutamab TELLOMAK Phase 2 trial in S é zary syndrome selected for oral presentation and preliminary data in Peripheral T Cell lymphoma to be displayed in a poster at ASH Annual Meeting 2023 ASH presentation on SAR443579/IPH6101, a potential first-in...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third q...

Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome selected for oral presentation Preliminary monotherapy lacutamab Phase 1b clinical data and pre-clinical combinability data in patients with per...